Built on an oxyntomodulin scaffold — a naturally occurring gut peptide that is itself a dual glucagon/GLP-1 agonist — rather than engineered from GLP-1 outward. The glucagon arm drives energy expenditure and hepatic fat mobilisation; the GLP-1 arm supplies appetite suppression and offsets glucagon's hyperglycaemic tendency.
Substantial Chinese phase 3 programme. The GLORY-2 study reported up to 20.1% weight reduction at the 9 mg dose, meeting primary and all key secondary endpoints. Evidence quality here is real and modern — the limitation is that it has been generated predominantly in Chinese populations and has not been reviewed by FDA.
Approved in China by the NMPA — for chronic weight management (June 2025) and for glycaemic control in type 2 diabetes (September 2025). It is the world's first dual GCG/GLP-1 agonist to reach approval anywhere. Not FDA-approved and not lawfully marketed in the US.
Trial safety data exist. Gastrointestinal effects and heart-rate increase, consistent with the class. Approval outside the US does not mean FDA has reviewed the dossier.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.